Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study. (May 2020)

• Record Type: Journal Article
• Authors: Ates Bulut, Esra; Sahin Alak, Zehra Yagmur; Dokuzlar, Ozge; Kocyigit, Suleyman Emre; Soysal, Pinar; Smith, Lee; Isik, Ahmet Turan
• Is Part Of: Archives of gerontology and geriatrics. Volume 88(2020)
• Publication Date: 2020-05
• Subjects: DPP-4 inhibitors -- Cognitive decline -- Metabolic outcome -- Diabetes mellitus -- Alzheimer's disease -- Older adults; Aging -- Periodicals; Geriatrics -- Periodicals; Gerontology -- Periodicals; Electronic journals; 305.26
• DOI: 10.1016/j.archger.2020.104013
• Languages: English
• ISSNs: 0167-4943

Abstract

Highlights: Type 2 Diabetes Mellitus shares several pathophysiological mechanisms with Alzheimer's Disease. Studies reported antidiabetic treatments such as intranasal insulin, GLP-1 analogs and DPP-4 inhibitors may also improve cognitive functions. DPP-4 inhibitors may have dual benefits by improving glycemic control and cognitive function in older adults. Abstract: Aims: Type 2 Diabetes Mellitus(DM) is a well-known risk factor for cognitive impairment. Recent evidences suggest that Dipeptidyl peptidase-4(DPP-4) inhibitors might have neuroprotective effects. Therefore, this study aimed to investigate vildagliptin, a DPP-4 inhibitor, effects on cognitive function in older patients with DM. Materials and Methods: A retrospective longitudinal clinical trial was carried out on total 130 subjects with type 2 DM. Patients underwent comprehensive geriatric assessment twice within six months interval. The patients were divided into three groups according to antidiabetic treatment: untreated control group (patients achieve individual goal HbA1c without antidiabetic medication), vildagliptin(+) group(patients using vildagliptin alone or combination) and the vildagliptin(–) group. Results: The mean age was 75.72 ± 7.46 years. The control group was older, of a lighter weight and also had a higher female gender ratio(p ≤ 0.01). When sex, age, educational level and metabolic profile were adjusted, there was only change in copying subdomain of Mini Mental State Examination between vildagliptin(+) and other groups at the end of 6 months. Vildagliptin also resulted in reduction of HbA1c and weight(p < 0.05). Conclusion: The addition of vildagliptin to treatment improved the copying subdomain of cognitive function and metabolic control of the older patients with type 2 DM within 6 months.